Replimune REPL
NASDAQ REPL
$11.72 +0.30 (+2.63%)
At close: Oct 21, 2026 · 4:00 PM EDT

Replimune (REPL) Depreciation & Amortization (CF) (2017 - 2026)

Updated

Replimune's Depreciation & Amortization (CF) came in at $937,000 for fiscal Q1 2027 (quarter ended Jun 30, 2026), up 4.1% from $900,000 a year earlier and up 28.0% from the prior quarter.

Analysis

Replimune (REPL) Depreciation & Amortization (CF) (2017 - 2026) Analysis & Trends

Over the trailing twelve months to Jun 30, 2026, Replimune reported Depreciation & Amortization (CF) of $3.27 million, down 9.2% year-over-year; for FY2026 (ended Mar 31, 2026), it was $3.33 million, down 4.9% from FY2025.

  • Depreciation & Amortization (CF) carries a five-year compound annual growth rate of 14.3% (FY2021 to FY2026).
  • Going back by fiscal year, Depreciation & Amortization (CF) was $3.5 million in FY2025 (+29.7%), $2.7 million in FY2024 (+10.3%), $2.45 million in FY2023 (+14.0%) and $2.15 million in FY2022 (+25.5%).
  • The fiscal Q1 2027 figure represents the highest quarterly Depreciation & Amortization (CF) since fiscal Q3 2025.
  • Year-over-year, Depreciation & Amortization (CF) increased in five of the last eight quarters, with growth averaging 9.1%.
  • The fastest year-over-year change in Depreciation & Amortization (CF) over five years came in fiscal Q3 2025 (growth of 42.9%), and the weakest in fiscal Q3 2026 (a decline of 20.0%).
  • Business Quant data shows REPL's Depreciation & Amortization (CF) at $732,000 (Q4 2026), $800,000 (Q3 2026) and $800,000 (Q2 2026) in the three fiscal quarters before Q1 2027.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Dep. & Amort. (Qtr)
1 Eli Lilly 1,136.97 Bn 1,105.55 Bn 19.71 Bn 534.00 Mn
2 Johnson & Johnson 619.72 Bn 538.25 Bn 17.26 Bn 1.96 Bn
3 AbbVie 503.40 Bn 476.52 Bn 12.70 Bn 194.00 Mn
4 Merck 370.15 Bn 324.53 Bn 12.21 Bn 599.00 Mn
5 Novartis Ag 298.64 Bn 262.63 Bn 11.24 Bn -
6 Astrazeneca 261.07 Bn 234.76 Bn 12.86 Bn 1.93 Bn
7 Amgen 237.00 Bn 192.40 Bn 7.24 Bn 1.11 Bn
8 Gilead Sciences 191.24 Bn 165.43 Bn 6.22 Bn 98.00 Mn
9 Pfizer 170.31 Bn 116.96 Bn 10.94 Bn 1.62 Bn
10 Replimune 1.14 Bn 79.22 Mn - 937,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 937,000.00
Mar 31, 2026 732,000.00
Dec 31, 2025 800,000.00
Sep 30, 2025 800,000.00
Jun 30, 2025 900,000.00
Mar 31, 2025 802,000.00
Dec 31, 2024 1.00 Mn
Sep 30, 2024 900,000.00
Jun 30, 2024 736,000.00
Mar 31, 2024 700,000.00
Dec 31, 2023 700,000.00
Sep 30, 2023 700,000.00
Jun 30, 2023 621,000.00
Mar 31, 2023 528,000.00
Dec 31, 2022 682,000.00
Sep 30, 2022 617,000.00
Jun 30, 2022 620,000.00
Mar 31, 2022 549,000.00
Dec 31, 2021 548,000.00
Sep 30, 2021 532,000.00
API Access

Replimune Depreciation & Amortization (CF) API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=depreciation-and-amortization-cf&ticker=REPL&period=max&api_key=YOUR_API_KEY